Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Genitourinary 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Breast 1

Conditions

Solitary Fibrous Tumor, Pleural 1Mesothelioma, Malignant 1

Interventions

Carboplatin 88pembrolizumab 77Pemetrexed 65Cisplatin 56Paclitaxel 33Docetaxel 31durvalumab 28atezolizumab 28Nivolumab 28Specimen Handling 25Magnetic Resonance Spectroscopy 20Gemcitabine 19osimertinib 18130-nm albumin-bound paclitaxel 18Etoposide 17Radiotherapy 14Cetuximab 14Platinum 12Taxes 11Immunoglobulin G 101,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Ipilimumab 9Disulfides 9Bevacizumab 9amivantamab 8Topotecan 8fludarabine 7Ramucirumab 7Radiosurgery 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
cediranib × Thoracic × 30 days × Clear all
NCT01064648 2026-05-29

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
117 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡